JENSCARE-B (09877) has announced that the group expects revenue for the six months ending June 30, 2026, to be approximately RMB 63 million to RMB 65 million, representing a year-on-year increase of 385% to 400%. Other income and gains are projected to be around RMB 9 million to RMB 11 million, bringing total income to approximately RMB 72 million to RMB 76 million. Compared to the same period last year, this represents an increase of RMB 47 million to RMB 51 million, or 188% to 204%.

The primary drivers for the performance growth during the reporting period include: 1. The continued commercial success of the group's transcatheter aortic valve system, Ken-Valve, which has generated steady revenue growth. Ken-Valve is suited for treating aortic regurgitation or combined stenosis, and its product design features and operational advantages have facilitated rapid adoption across multi-level healthcare institutions. 2. The group's range of structural heart disease interventional products is actively being used in paid clinical implantations overseas. The strong clinical outcomes and application benefits of these products have received high praise from global key opinion leaders and experts, addressing a significant, long-standing unmet clinical need in the global structural heart disease market.

Furthermore, the group will continue to advance the development of multiple innovative product pipelines and deepen its international commercial footprint to achieve rapid revenue growth. It will also enhance management efficiency and reduce operational costs in production, supply chain, and operational management to achieve its long-term strategic development goals.